Department of Health and Human Services September 20, 2011 – Federal Register Recent Federal Regulation Documents
Results 1 - 13 of 13
Animal Drug User Fee Act; Public Meeting; Request for Comments
The Food and Drug Administration (FDA) is announcing a public meeting on the Animal Drug User Fee Act (ADUFA). FDA invites public comment on the ADUFA program and suggestions regarding the features FDA should propose for the next ADUFA program. Date and Time: The meeting will be held on November 7, 2011, from 9 a.m. to 12 noon. Location: The meeting will be held at the Food and Drug Administration, 7519 Standish Pl., 3d floor, Rm. A, Rockville, MD 20855. If you require special accommodations, please contact Patricia Arnwine (see Contact Person) at least 7 days before the meeting. Contact Person: Donal Parks, Food and Drug Administration, Center for Veterinary Medicine, 7519 Standish Pl., Rockville, MD 20855, 240- 276-8688, FAX: 240-276-9744, Donal.Parks@fda.hhs.gov, or Patricia Arnwine, Food and Drug Administration, Center for Veterinary Medicine, 7519 Standish Pl., Rockville, MD 20855, 240-276-9724, FAX: 240-276- 9744, Patricia.Arnwine@fda.hhs.gov. Comments: Regardless of attendance at the meeting, interested persons may submit either electronic or written comments regarding this document. Submit electronic comments to https://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA- 305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Identify comments with the docket number found in brackets in the heading of this document. Comments received by October 26, 2011, will be taken into consideration before the public meeting. Transcripts: Transcripts of the meeting will be available for review at the Division of Dockets Management and on the Internet at https://www.fda.gov/ForIndustry/UserFees/AnimalDrugUserFeeActA DUFA/ ucm042891.htm approximately 30 days after the meeting.
Magnetic Resonance Imaging Safety; Public Workshop
The Food and Drug Administration (FDA) is announcing a public workshop entitled: ``Magnetic Resonance Imaging (MRI) Safety Public Workshop.'' The purpose of the public workshop is to discuss factors affecting the safe use of magnetic resonance imaging (MRI) and approaches to mitigate risks. The overall goal is to discuss strategies to minimize patient and staff risk in the MRI environment.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.